Absence of mutations in the HBsAg “a” determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Hepatology"
DOI: 10.1016/s0168-8278(17)30822-x
Abstract: CONTACT INFORMATION Mahtab et al., 2016. Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naïve Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. PLOS ONE 2016; 11: e156667 Martin… read more here.
Keywords: determinant rep; absence mutations; hbsag determinant; 2139 therapy ... See more keywords
REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection.
Sign Up to like & getrecommendations! Published in 2019 at "ACS infectious diseases"
DOI: 10.1021/acsinfecdis.8b00156
Abstract: Nucleic acid polymers (NAPs) are broad spectrum antiviral agents whose antiviral activity in hepatitis B virus (HBV) infection is derived from their ability to block the release of the hepatitis B virus surface antigen (HBsAg).… read more here.
Keywords: hbv hdv; infection; hbv; rep 2139 ... See more keywords
Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-64122-0
Abstract: Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) for its assembly and release. Current HBV treatments are only marginally effective against HDV because they fail to inhibit HBsAg production/secretion. However, monotherapy with the… read more here.
Keywords: rep 2139; hepatitis virus; acid polymer; hdv ... See more keywords